Subscribe today
Get Cruise Critic in your inbox
Cruise News
Home > Cruise News Archive > More Swine Flu: Pullmantur Cruise Ship Denied Entry to Grenada
Date Published: June 16, 2009
Pullmantur Profile and Reviews
Latest Cruise News Headlines
More Swine Flu: Pullmantur Cruise Ship Denied Entry to Grenada
(6:37 p.m.) -- A Pullmantur cruise ship, Ocean Dream, was barred from disembarking passengers in Grenada yesterday due to suspected cases of H1N1 (the virus formerly known as swine flu) onboard, reports the Caribbean Broadcasting Corporation and Grenada Broadcasting Network. Pullmantur is a Spanish cruise line owned by Royal Caribbean Cruises Ltd.

The 35,000-ton, 1,350-passenger Ocean Dream docked in Grenada on Monday morning, and reported that around 40 crewmembers were exhibiting flu-like symptoms. The Ministry of Health refused to allow any crew or passengers to disembark the ship as a precautionary measure. Grenada is ill equipped to deal with an outbreak of H1N1, and -- as the Director of Health Services told the Grenada Broadcasting Network -- the main medical center does not have enough respirators to handle flu patients.

Ocean Dream is sailing seven-night Southern Caribbean cruises roundtrip from Aruba. It was scheduled to call in St. Lucia today and Barbados on Wednesday. Royal Caribbean could not be reached for comment as to whether these calls have been or will be affected.

Previously this spring, P&O Australia's Pacific Dawn was barred from Australian ports and Royal Caribbean's Adventure of the Seas was denied entry to St. Lucia and Antigua because of suspected cases of H1N1.

--by Erica Silverstein, Senior Editor

Fan Us on Facebook!
Follow Us on Twitter!
Cruise News Headlines
More Pullmantur News
Pullmantur Reviews

About UsAdvertisingEditorial DisclaimerPress
PrivacySite MapStoreSubscribe
X

Thank You For Signing Up!

Please Note: To ensure delivery of your free e-letters, please add news@cruisecritic.com to your address book.

We're committed to protecting your privacy and will not rent or sell your e-mail address. By proceeding, you agree to our Privacy Policy and Terms of Use.